National Center for Advancing Translational Sciences


The National Center for Advancing Translational Sciences was established on December 23, 2011 and is located in Bethesda, Maryland. NCATS is one of 27 institutes and centers of the U.S. National Institutes of Health, an agency of the U.S. Department of Health and Human Services. The mission of NCATS is to transform scientific discoveries into new treatments and cures for disease that can be delivered faster to patients. The budget provided to NCATS for fiscal year 2018 is $557,373,000.

History

NCATS was created on December 23, 2011 by the Consolidated Appropriations Act, 2012.
The center was created from a number of existing NIH programs:

Directors

Past directors 2011 – present
PortraitDirectorTook officeLeft office
actingThomas R. InselDecember 23, 2011September 22, 2012
1Christopher P. AustinSeptember 23, 2012April 15, 2021
actingJoni L. RutterApril 16, 2021November 5, 2022
2Joni L. RutterNovember 6, 2022Present

Divisions

NCATS is organized into a number of divisions:

Programs and initiatives

Overview

The stated goal of NCATS is to promote research in both existing and new areas of medicine and science, in order to promote public health and to overcome high failure rates in clinical trials. To accomplish this, NCATS supports 31 programs and initiatives that relate to translational research and improving the speed of therapeutic development. The 31 programs and initiatives involve a range of STEM-related fields including biology, biochemistry, chemistry, bioengineering, virology, genetics, and data science. Within the realm of translational science, issues that NCATS is particularly focused on addressing using its programs, initiatives, and partnerships include increasing the success and de-risking the costs associated with therapeutic development, incentivizing more collaborative work, and addressing data transparency issues.

COVID response

During the COVID-19 pandemic, NCATS launched an open data initiative to promote collaborative sharing of COVID-related drug data. An additional data sharing partnership with several other government institutes resulted in a study detailing the COVID-related risks for patients with chronic obstructive pulmonary disease.